AbCellera Biologics (ABCL) Return on Sales (2020 - 2023)
Historic Return on Sales for AbCellera Biologics (ABCL) over the last 5 years, with Q3 2024 value amounting to 5.14%.
- AbCellera Biologics' Return on Sales fell 8000.0% to 5.14% in Q3 2024 from the same period last year, while for Sep 2024 it was 5.14%, marking a year-over-year decrease of 25700.0%. This contributed to the annual value of 5.65% for FY2024, which is 18000.0% down from last year.
- As of Q3 2024, AbCellera Biologics' Return on Sales stood at 5.14%, which was down 8000.0% from 4.8% recorded in Q2 2024.
- In the past 5 years, AbCellera Biologics' Return on Sales ranged from a high of 0.78% in Q4 2020 and a low of 5.14% during Q4 2023
- For the 5-year period, AbCellera Biologics' Return on Sales averaged around 1.73%, with its median value being 0.45% (2020).
- Per our database at Business Quant, AbCellera Biologics' Return on Sales soared by 41400bps in 2022 and then plummeted by -46000bps in 2023.
- Over the past 5 years, AbCellera Biologics' Return on Sales (Quarter) stood at 0.78% in 2020, then plummeted by -44bps to 0.43% in 2021, then crashed by -422bps to 1.39% in 2022, then plummeted by -270bps to 5.14% in 2023, then changed by 0bps to 5.14% in 2024.
- Its last three reported values are 5.14% in Q3 2024, 4.8% for Q2 2024, and 4.11% during Q1 2024.